Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ -513,236
▲ 42% vs 2024
Profit
Caution€ -8 million
▼ 143% vs 2024
Debts
Low€ 5.6 million
▲ 482% vs 2024
ATB THERAPEUTICS from Marche-en-Famenne, company number BE0677980015, closed financial year 2025 with a result of € -8 million after tax. For that financial year ATB THERAPEUTICS recorded a gross margin of € -513,236 and equity of € 5.1 million. Compared with financial year 2024, the result moved from € -3.3 million to € -8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
What happened at ATB THERAPEUTICS?
What happened at ATB THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Magman stepped down as director. NBB
- MRL Ventures Fund LLC stepped down as director. NBB
- LSP 7 Coöperatief U.A. stepped down as director. NBB
- CAPITAL ET CROISSANCE stepped down as director. NBB
- CHITON ROCKS stepped down as director. NBB
- V-Bio Fund 2 stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 8 million. Source: NBB ↗
- New establishment in Gent. KBO
In short
From € 1.2 million loss in 2021 to € 8 million loss in 2025.
Paid € 188 in corporate taxes since 2021.
On average € 30,200 of value added per employee in 2022.
A new publication or filing at ATB THERAPEUTICS? We notify you, reason included.
Follow ATB THERAPEUTICSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Managing director · represented by Bertrand Magy
since 2024 · until 2030
Director · represented by Karin Kleinhans
since 2024 · until 2030
Director · represented by John de Koning, Vincent Brichard
since 2024 · until 2030
Director · represented by Pierre Detrixhe
Also active at: CONCEPTEXPO GROUP, COLONA, MEGAFORM +34 more
since 2024 · until 2030
CHITON ROCKS
Director · represented by Mark Throsby
since 2024 · until 2030
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Aye, Rue de la Science 8
6900 Marche-en-Famenne
Suzanne Tassierstraat 1
9052 Gent
Active since 1 June 2025
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
Association pour le développement des Productions Agroalimentaires de qualité
CER-Groupe
€ 22.4 million revenue · 2025
Association pour l'Usage et la Défense de l'Appellation Jambon d'Ardenne
Orgenesis (Belgium)
€ 1.4 million gross margin · 2021
RevaTis
€ 136,602 gross margin · 2025
+7 more
Details
- Company number
- 0677.980.015
- VAT number
- BE 0677.980.015
- Registered office
- Aye, Rue de la Science 8, 6900 Marche-en-Famenne
- Names & denominations
- ATB THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 2017
- Peppol
- Active · Active since 7 Jul 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van farmaceutische grondstoffen
Teelt van specerijgewassen en van aromatische en medicinale gewassen